Elanco Animal Health Incorporated (NYSE:ELAN) Shares Purchased by Shapiro Capital Management LLC

Shapiro Capital Management LLC grew its holdings in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 7.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 12,356,702 shares of the company's stock after buying an additional 862,900 shares during the quarter. Elanco Animal Health accounts for about 5.1% of Shapiro Capital Management LLC's investment portfolio, making the stock its largest holding. Shapiro Capital Management LLC owned about 2.50% of Elanco Animal Health worth $149,640,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in the company. Hillsdale Investment Management Inc. lifted its stake in Elanco Animal Health by 2.1% during the fourth quarter. Hillsdale Investment Management Inc. now owns 43,300 shares of the company's stock worth $524,000 after purchasing an additional 900 shares during the last quarter. Arizona State Retirement System increased its position in Elanco Animal Health by 0.8% in the fourth quarter. Arizona State Retirement System now owns 143,462 shares of the company's stock worth $1,737,000 after buying an additional 1,166 shares during the period. MTM Investment Management LLC increased its position in Elanco Animal Health by 9.3% in the fourth quarter. MTM Investment Management LLC now owns 14,168 shares of the company's stock worth $172,000 after buying an additional 1,200 shares during the period. Freedom Investment Management Inc. increased its position in Elanco Animal Health by 9.1% in the fourth quarter. Freedom Investment Management Inc. now owns 20,746 shares of the company's stock worth $251,000 after buying an additional 1,725 shares during the period. Finally, Blue Trust Inc. increased its position in Elanco Animal Health by 47.7% in the fourth quarter. Blue Trust Inc. now owns 5,862 shares of the company's stock worth $71,000 after buying an additional 1,894 shares during the period. 97.48% of the stock is currently owned by institutional investors.

Insider Activity at Elanco Animal Health

In other Elanco Animal Health news, Director Lawrence Erik Kurzius acquired 10,000 shares of the firm's stock in a transaction on Tuesday, March 11th. The stock was purchased at an average cost of $10.20 per share, for a total transaction of $102,000.00. Following the transaction, the director now owns 111,459 shares of the company's stock, valued at $1,136,881.80. The trade was a 9.86% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.89% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the company. Piper Sandler dropped their target price on Elanco Animal Health from $16.00 to $12.00 and set a "neutral" rating on the stock in a research report on Thursday, March 6th. UBS Group dropped their target price on Elanco Animal Health from $18.00 to $17.00 and set a "buy" rating on the stock in a research report on Wednesday, February 26th. Stifel Nicolaus increased their target price on Elanco Animal Health from $15.00 to $16.00 and gave the stock a "buy" rating in a research report on Monday. Morgan Stanley lowered their price target on Elanco Animal Health from $14.00 to $13.00 and set an "equal weight" rating on the stock in a report on Wednesday, February 26th. Finally, Barclays lowered their price target on Elanco Animal Health from $20.00 to $19.00 and set an "overweight" rating on the stock in a report on Wednesday, February 26th. Four investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $15.17.

Elanco Animal Health Price Performance

NYSE:ELAN traded up $0.32 during mid-day trading on Monday, reaching $13.24. 7,555,799 shares of the stock were exchanged, compared to its average volume of 5,052,521. The business has a fifty day moving average price of $10.16 and a 200 day moving average price of $11.44. The firm has a market capitalization of $6.58 billion, a PE ratio of 33.10, a PEG ratio of 2.50 and a beta of 1.49. Elanco Animal Health Incorporated has a 1-year low of $8.02 and a 1-year high of $18.80. The company has a current ratio of 2.55, a quick ratio of 1.31 and a debt-to-equity ratio of 0.66.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last released its earnings results on Wednesday, May 7th. The company reported $0.37 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.31 by $0.06. Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The firm had revenue of $1.19 billion for the quarter, compared to analyst estimates of $1.17 billion. During the same period in the previous year, the company earned $0.34 earnings per share. Elanco Animal Health's revenue was down 1.0% compared to the same quarter last year. Research analysts expect that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.